Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus FLUOCET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus FLUOCET.
ARAZLO vs FLUOCET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin into presynaptic neurons.
Topical: Apply 0.045% gel once daily to affected areas of the face.
20 mg orally once daily in the morning.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Fluoxetine: 4-6 days (single dose), 4-6 days (chronic); Norfluoxetine: 16 days. Clinical context: Steady state achieved after 4-5 weeks; extended half-life reduces withdrawal risk but prolongs washout.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal: 80% as fluoxetine and its metabolites (60% as glucuronide conjugates, 20% as parent and norfluoxetine). Fecal: 15% (biliary).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid